2008年4月16日星期三



1.,,,,,
2.,,.:,.",!"
|||3.*,,,:",,"
4..CBC()BC()ABC()ICBC()CMSB
5.:? :.:?.:?--!
6.,,"!!"!!:!
7.,,,;;;,,?
8.:
9.:,:,;sj,sj;sj
10.,,,?,!,!:?:.
|||11., : : , ,:,!
12..,,.,,.
13.(_!_) (__!__) (!) (_._) (_*_) (_o_)
14., ,,,:
15.,,,,
16. ?
17.:?:,.:60.: ,.:100
18.:?:.
19.,?:,,,,,
20.:;;;.
|||21.:.?...:?!.
22.: : ()TMD!
23.
24.,,.,,:,!
25.,,,50,,:.
26.,,,,:,:,:.
27.?,,,.!
28.,,,,,:,!
29.,'',''.,:,'
30.:m,a,y,d,b,:"----"
31.:
32.,..*
|||33.
34.:B
35.::******;:****** .:**
36.** **:,,
37.xo999,
38.,. ,:.:?!.
39..,**,,::,!
40.:**!,:**,?,:**,.
41.*"**"
42.:;;;;,;;.
|||43.,.:..*!
44. * !
45.:!:
46.,.,,:,,: .:,.:
47.,,,,?,,,,,!
48.,.:::.:.,:.
49.'',,,,:?
50.,:.:.,.:,!
51.,:;:::::!:!
52.,,:!,!
53.,,'',,:''!
54.**,,,,:,!
55.:**!,:**,?,:**,.
56.,,,,,,!
57..:?:.:?:.:!
|||58,;,:,();:,();:!
59.''' '
60.
61.
62.
63.
64.
65.:50:
66.::::
67.,,.,,:*,!
68.:!*.?,,,.
69.,,,*,,:'!!!,'
|||70.,,,*,,,!
71.*4000.,4000'*',4000!

11111111111111

2222222222222222222

2008年4月5日星期六

Chefs warn on side-effects of sushi boom


TOKYO (Reuters) -
As Japanese sushi conquers restaurants
and homes around the world, industry experts are fighting the
side-effects of the raw fish boom: fake sushi bars,
over-confident amateurs, poisoned consumers.


Once a rare and exotic treat, seaweed rolls and bites of
raw tuna on vinegared rice are now familiar to most food fans.
So familiar, in fact, that many hobby cooks in Europe and the
United States like to make them in their own kitchens.


But chefs and sushi experts at an international restaurant
summit in Tokyo warned of a lack of awareness in handling raw
fish among amateurs and some restaurateurs who enter the
profitable industry without sufficient training.


"Everybody thinks: %26#39;sushi is so expensive -- I can buy
cheap fish, fresh fish, I can make it at home.%26#39; It%26#39;s not true.
Not every fish is suitable to eat raw," chef and restaurateur
Yoshi Tome told Reuters.


Tome%26#39;s restaurant, "Sushi Ran" in Sausalito, California,
was awarded a Michelin star and he often advises customers on
preparing Japanese food.


He sees himself as an educator as well as a chef, and
believes that more and better training opportunities are needed
to prevent food scandals that could hurt the entire industry.


"I get these questions all the time -- people call me: %26#39;Hey
Yoshi, my husband went to fish a big salmon, we%26#39;re looking to
eat it as sashimi. We opened it and a bunch of worms came out.
Can we eat it?"%26#39;


His answer: you cannot eat it as sashimi; but you can throw
away the affected parts and cook and eat the rest.


In fact, Tome said salmon, which is prone to parasites,
should never be eaten raw but be cooked, marinated, or frozen
before being consumed.


He described another case in which an inexperienced
restaurateur in the United States served raw baby crab. This
lead to cases of food poisoning and prompted a recall of that
type of crab. Tome serves the crab deep-fried at his restaurant
and says it is perfectly safe if prepared the right way.


"Here in Japan, some people eat raw chicken, chicken
sashimi. But we know chicken can have salmonella, so in the
U.S. nobody eats raw chicken," he added.


SUSHI POLICE


Japan%26#39;s bureaucrats drew criticism and ridicule a year ago
with a plan to create a global "sushi police" that would assess
Japanese restaurants overseas. Since then, there has been a
change of tactics, and the emphasis is now on education and
advice rather than uninvited checks.


Ryuji Ishii, who runs the Advanced Fresh Concepts Franchise
Corp, the largest supplier of fresh sushi to supermarkets in
the United States, finds that education is important not just
for food safety purposes.


Ishii is rolling out his ready-to-eat sushi range in
Wal-Mart supermarkets, having opened almost 90 sushi stalls
since last September. They are planning some 400 stores in
total.


But bringing raw fish and seaweed to middle America takes
some work -- Ishii cautiously described the sales as "decent."


"The challenge is, we have never dealt with that market. So
far, we%26#39;ve been dealing with a very upscale market, high-end
supermarkets," he said in an interview on the sidelines of the
two-day summit, organized by the Organization to Promote
Japanese Restaurants Abroad.


"In order to become really mainstream, we have to overcome
the Wal-Mart consumers," Ishii said. "We need more time to
educate the consumers."


He tries to tempt shoppers with samples of the most popular
type of sushi in the United States: the California Roll, made
with avocado. Purists might argue that the California Roll, a
U.S. invention, is not real sushi anyway, but Ishii says it
allows customers to have a first taste of Japanese food and
then get hooked on more exotic items -- the ones that include
raw fish.


(Reporting by Sophie Hardach; Editing by Alex Richardson)

The man who made lists to fend off depression


LOS ANGELES (Reuters) -
His mother suffered dark
depressions and tried to dominate his life. His sister and
daughter had severe mental problems, his father and wife died
young and a beloved uncle committed suicide in his arms.


So what did Peter Mark Roget, the creator of Roget%26#39;s
Thesaurus, do to handle all the pain, grief, sorrow,
affliction, woe, bitterness, unhappiness and misery in a life
that lasted over 90 years?


He made lists.


The 19th century British scientist made lists of words,
creating synonyms for all occasions that ultimately helped make
life easier for term paper writers, crossword puzzle lovers and
anyone looking for the answer to the age-old question: "What%26#39;s
another word for ..."


And according to a new biography, making his lists saved
Roget%26#39;s life and by keeping him from succumbing to the
depression and misery of those around him.


"As a boy he stumbled upon a remarkable discovery -- that
compiling lists of words could provide solace, no matter what
misfortunes may befall him," says Joshua Kendall author of the
just published "The Man Who Made Lists" (Putnam, %26#36;25.95), a
study of Roget%26#39;s life (1779 to 1869) based on diaries, letters
and even an autobiography composed of lists.


Kendall, in a recent interview, said Roget cared more for
words than people and that making lists on the scale that he
did was obsessive-compulsive behavior that helped him fend off
the demons that terrorized his distinguished British family.


Madness was a regular guest in Roget%26#39;s home, Kendall said.
One of his grandmothers either had schizophrenia or severe
depression, Roget%26#39;s mother lapsed into paranoia, often accusing
the servants of plotting against her. Both his sister and his
daughter suffered depression and mental problems.


Then there was the case of Roget%26#39;s uncle, British member of
Parliament Sir Samuel Romilly, known for his opposition to the
slave trade and for his support of civil liberties. He slit his
own throat while Roget tried to get the razor out of his hands.


Unlike a Thesaurus, no one understood Uncle Sam%26#39;s last
words: "My dear....I wish..."


Indeed, to quote most of the Thesaurus listing for pain,
Roget%26#39;s was a life filled with grief, pain, suffering,
distress, affliction, woe, bitterness, heartache, unhappiness,
infelicity and misery.


NOT WHOLLY EVIL


Kendall said, "The lists gave him an alternative world to
which to repair." Many writers have declared their debt to
Roget, including Peter Pan%26#39;s creator, J.M. Barrie. In homage,
he put a copy of the Thesaurus in Captain Hook%26#39;s cabin so he
could declare: "The man is not wholly evil -- he has a
Thesaurus in his cabin.


The 20th century poet Sylvia Plath called herself "Roget%26#39;s
Strumpet" to pay respects for all the word choices he gave her.


But the British journalist Simon Winchester holds Roget
responsible for helping to dumb down Western culture because
his work allows a writer to look it up rather than think it
out.


Roget made his first attempt at a Thesaurus at age 26 but
put aside the effort and did not publish his book until 1852
when he was in his 70s and retired. He then kept busy with it
for the rest of his life.


It became an instant hit in Britain but did not sell that
well when an American edition was published two years later.
But when Americans went crazy for crossword puzzles in the
1920s, the Thesaurus assumed its place on reference shelves.


Kendall%26#39;s book is written in a style that he calls
"narrative non-fiction" which contains a lot of dialogue and
descriptions of how Roget and his friends feel and think, all,
he says, based on source material.


"I did a lot of work to stitch together a narrative," he
said, adding that all the scenes in the book are based on
actual events.

Italy recalls contaminated mozzarella cheese


ROME (Reuters) -
Italy ordered a recall on Friday of
mozzarella cheese potentially contaminated with cancer-causing
dioxin, as a widening health scare tainted the reputation of
one of its best-known culinary products.


Italy%26#39;s Health Ministry said it was withdrawing products
from 25 companies in Campania region, where Italy%26#39;s best
buffalo mozzarella is produced.


News of the recall came moments after France joined a small
group of nations that have decided to halt sales of some
Italian mozzarella, despite Italy%26#39;s assurances that none of the
suspect cheese was exported. Japan and South Korea had already
stopped imports.


The European Commission, which had previously threatened a
trade ban unless Rome acted more aggressively, said it was
satisfied with Italy%26#39;s latest effort to contain the scare.


Italian Foreign Minister Massimo D%26#39;Alema played down the
health risks even as he announced a recall affecting an
industry which employs 20,000 people and is worth about 300
million euros (%26#36;475 million) a year.


"This is a limited phenomenon and once the (recall)
measures are completed, we%26#39;re convinced that we can restore
confidence in the quality of a product that remains a symbol of
Italian gastronomy," he said.


In Brussels, the European Commission said Italy had also
pledged to carry out "constant monitoring" of production sites
to ensure no further cases of mozzarella cheese were found with
dioxin levels exceeding the EU%26#39;s maximum permitted levels.


"Taking into account the information that was given today,
there is no reason at this stage to take further action at EU
level," said Nina Papadoulaki, Commission health spokeswoman.


GARBAGE CRISIS


Italian health officials believe the dioxin is linked to a
recent garbage crisis in Naples and the surrounding Campania
region.


With dumps in the area full, locals burned piles of rubbish
in the streets and in open fields. Health officials say
industrial waste was also set ablaze, spreading fumes that in
some cases contained dioxin, a toxic chemical.


The bad publicity has made some Italian consumers wary. One
mozzarella dealer in Rome said sales to hotels and restaurants
had fallen by half.


"We are at the historical minimum level of sales," said
dealer Paolo Micocci, comparing the mozzarella scare to panic
over mad cow disease and bird flu.


"Scares have hit cows, then fish with mercury, then
chicken. ... Now, it%26#39;s our turn. We%26#39;ll hang in there."


Italy produces about 33,000 tonnes of buffalo mozzarella a
year, with 16 percent of it sold abroad, mostly in the European
Union. France and Germany are the major importers but sales
have been expanding to other countries, including Japan and
Russia.


France ordered its shops on Friday to stop selling all
mozzarella cheese from Italy%26#39;s Campania region, saying it was
"as a precautionary measure" pending further tests.


But German authorities said no such move was necessary
since Italian authorities had assured them that none of the
affected mozzarella from Campania was exported to EU countries.


Italy%26#39;s biggest farmers%26#39; group Coldiretti criticized
France, saying the health scare was based on emotion, not
science.


"France%26#39;s reaction is emotional. It follows the wave of
emotional reactions in Japan and Korea," said Rolando
Manfredini, food safety expert at Coldiretti.


(Additional reporting by Crispian Balmer in Paris, Jeremy
Smith in Brussels, Erik Kirschbaum in Berlin, Roberto Landucci
and Antonio Denti in Rome, and Svetlana Kovalyova in Milan,
editing by Mary Gabriel)

Red Cross launches China HIV prevention programme


BEIJING (AFP) -
The Red Cross Society of China on Friday launched its first ever nationwide HIV programme with the aim of reaching all 31 provinces and municipalities in the country by 2010.





The organisation, which first got involved in HIV work in 1994 in the southwestern province of Yunnan, said it aimed to upscale its HIV prevention work across the country over the next three years.




In 2007, just 22 out of 31 provinces had undertaken or were undertaking HIV projects, the organisation said.




It plans to prevent further infection through peer education and the spread of information, to expand care and support for those affected by HIV, and to reduce the stigma and discrimination associated with the disease.




An estimated 700,000 people in China are currently living with HIV, according to information compiled by the government and the United Nations.




Last year, an estimated 50,000 people became newly infected with the virus, and an estimated 20,000 people died of AIDS, the Red Cross Society of China said.




But the overall numbers may be considerably higher as many HIV cases still go unreported, and testing is not widespread, according to the organisation.




The Chinese government has in recent years stepped up its campaign against AIDS.




In February, authorities launched their first anti-AIDS programme focused on gay men.




At the same time, though, one of the nation%26#39;s most prominent AIDS campaigners, Hu Jia, is on trial for incitement to subvert state power.




A verdict on the case is expected soon.

Latest in cardiovascular care on display in Chicago confab


WASHINGTON (AFP) -
American cardiologists convene in Chicago this weekend for the world%26#39;s largest confab on heart disease, where results of major clinical trials that could influence medical practice will be unveiled.





"We are very excited about the meeting, there is going to be a lot of very important science presentations and some of them will transform the way we practice as we are going forward," said cardiologist Marc Shelton, chair of the American College of Cardiology%26#39;s 57th annual gathering.




The results of dozens of clinical trials will be unveiled during the three-and-a half-day meeting, opening Saturday and expected to draw some 18,000 participants, Shelton told reporters.




Of particular note is a forum on the controversial ENHANCE trial comparing US pharmaceutical giant Merck%26#39;s anti-cholesterol drug Vytorin with simvastatin, a predecessor from the same group that is now available in a low-cost generic version.




Although the clinical trial was concluded in 2006, Merck and Schering-Plough -- the maker of Zetia, another cholesterol-buster combined with simvastatin to create Vytorin -- waited until January 2008 to release the findings.




They show little apparent difference between Vytorin and simvastatin in patients with very high levels of cholesterol, although the former is five times as expensive as the latter.




The revelation caused sales of Vytorin and Zetia to drop by 18 percent and sent shares of the two pharmaceuticals plunging.




Following an aggressive advertising campaign launched in 2006, sales of Vytorin and Zetia had doubled in two years, bringing in five billion dollars world wide in 2007.




The results of the ENHANCE clinical trial will be discussed in a forum of eminent cardiologists Sunday, the second day of the conference.




"The goal that we have given to the panel members is to, at the end of the discussions, come up with a recommendation for how they would treat patients when they go home on Wednesday after the meeting," Shelton said.







A congressional panel has also launched a fraud investigation of the two companies.





Statins such as simvastatin, Pfizer%26#39;s lipitor, and AstraZeneca%26#39;s crestor act by blocking an enzyme in the liver, while Zetia absorbs cholesterol in the digestive tract.




The latter approach has not been proved to lower the risk of heart attack by reducing arterial plaque.




Several other important studies will be presented in Chicago this weekend, Shelton said.




A vast international clinical trial dubbed ONTARGET should provide epidemiological data on the best treatment for high blood pressure, after testing anti-hypertension medicines Telmisartan and Ramipril separately and in combination.




Other clinical trials involve hypertension treatment in patients over age 80 with obesity or high-risk diabetes.




Cardiovascular disease is the chief cause of death in the United States, claiming more than 900,000 lives each year.




It was responsible for 17.5 million deaths in the world in 2005, 30 percent of the total mortality, according to the World Health Organization.

S.Africa to track down TB patients


JOHANNESBURG (AFP) -
South Africa on Friday launched a four million dollar programme to track down tuberculosis patients who have defaulted treatment, leading to resistant strains of the illness.





Health Minister Manto Tshabalala-Msimang, speaking in the Northern Cape on TB Day, said all nine provinces had established TB tracer teams of nurses and community health workers to follow up on patients who had defaulted treatment.




"These teams visit homes to find patients so that they can put them back on treatment. To further strengthen this programme, the national department has deployed an additional 72 teams in sub-districts which have poor TB outcomes," she said.




Tshabalala-Msimang said the 33 million rand (four million dollars / 2.5 million euros) programme hoped to improve treatment outcomes and prevent the development of drug resistant TB.




South Africa is desperately trying to curb its heavy caseload of TB. With more than 340,000 South Africans infected, patients defaulting from treatment have developed multi-drug resistant (MDR) and extreme drug resistant (XDR) TB.




Resistance to TB drugs can develop when patients fail to take their medication as prescribed, and in a minority of cases through direct transmission from person to person.




MDR-TB fails to react to the two most powerful anti-TB drugs, while XDR-TB is resistant to these and at least two others.




Nearly 400 cases of XDR-TB were diagnosed in 2007.




Tshabalala-Msimang said 400 million rand devoted by government to fighting TB was being used to improve the conditions of hospital isolation of patients.




The government decided to isolate people who have a history of defaulting treatment. Patients have broken out of hospital in frustration at the lengthy time medical care takes.




"It is in the interest of the public as well as these patients that XDR and MDR patients remain in hospital until they are discharged," the minister said.




She said TB plans had already brought defaulter rates to 8.8 percent in the first half of 2006 down from 9.7 percent in 2005, while the national cure rate went from 68.3 percent to 73.6 percent in the same period.

Italians wary of mozzarella scare but eat on


MILAN (Reuters) -
Carefully selecting a lump of fine
buffalo mozzarella, a Milan cheesemonger points to a
certificate stuck to the glass-fronted fridge which is meant to
appease cautious customers about its origins and quality.


Ever since news broke that some of Italy%26#39;s best mozzarella
was being made with milk contaminated with cancer-causing
dioxin, Alfredo says customers have been hesitant to buy the
cheese until they know where it comes from.


"People see what is happening and they are scared," said
the cheesemonger, who asked to be identified by his first name
only.


"There has been a small impact. We put up the certificate
to show where our product comes from and that helps."


Buffalo mozzarella is one of Italy%26#39;s best known culinary
specialties and a byword for fresh and natural Italian produce.
It is known abroad for its use on pizza, but purists eat it on
its own or with a drizzle of extra-virgin olive oil.


The cheese costs at least twice as much as mozzarella made
with cow%26#39;s milk, and Italy makes 33,000 tonnes of it a year, 16
percent of which is sold abroad.


Seeking to avert a major food scare, Italy has sealed off
83 dairy farms in the southern Campania region around Naples
after finding nearly one in five buffalo mozzarella producers
were making cheese with higher-than-permitted levels of dioxin.


Italy has told the European Commission it has not exported
any contaminated mozzarella but it took the precaution on
Friday of ordering a recall of cheese from 25 affected
producers from Campania, where Italy%26#39;s best buffalo mozzarella
is produced.


"Seeing what is happening to a symbol of Italian produce
makes you want to cry," said Lino Stoppani of upmarket Milan
food shop Peck. "We have seen caution. Customers are sensitive.
Certainly, there has been a fall in mozzarella consumption."


HEALTH RISKS


Officials believe the dioxin levels are linked to a recent
garbage crisis in Naples and nearby Campania area, where locals
burned rubbish in streets and open fields as dumps were full.


Police have also been investigating whether feed given to
buffalo herds was tainted, possibly by gangsters linked to
illegal waste disposal.


Italian officials are playing down health risks for the
public and say special checks are being made to guarantee the
safety of the cheese.


A consumer group has advised Italians not to eat it until
the final results of tests and the names of the producers
concerned are made public. A leading group of producers said
sales were down 30 percent in the first two months of the year,
with a revenue loss of 30 million euros (%26#36;47.29 million).


On Friday, France briefly prohibited sales of some Italian
mozzarella, but later lifted the order after winning assurances
from Rome that none of the suspect cheese was exported there.


Japan and South Korea have stopped imports of buffalo
mozzarella over contamination concerns.


But some consumers in Italy say they are not fearful.


"My first reaction was not to eat it as this is scary,"
said Milanese pensioner Mario Rossi as he shopped in a
supermarket, where rows of mozzarella cheese were stacked,
untouched. "But I will continue eating it, though with
caution."


At Milan%26#39;s Obika Mozzarella Bar, a restaurant specializing
in quality mozzarella, diners happily munched on the cheese.
The restaurant, which has branches in Rome and London as well,
says it has not felt any impact from the scare so far.


"Our clients trust us. ... This is something that has
scared a lot of people but it is a case of counterfeit,"
founder Silvio Ursini said by phone, underlining that all
cheese used by his restaurants undergoes thorough checks.


Pizzeria owner Pino Malastrana was not worried either.


"I buy four kilograms of it a day," he said, tucking into a
plate of buffalo mozzarella. "And I%26#39;ve been using it all up."


(Editing by Mary Gabriel)

WTO rules against US, Canada in beef row with EU


GENEVA (AFP) -
The World Trade Organisation has ruled against the United States and Canada in a row with the European Union over an EU ban on beef treated with growth hormones, a European official told AFP on Friday.





The WTO has found that penalities imposed by the US and Canada on some EU products in retaliation for the EU ban are illegal, said the official, who asked not to be named.




"The sanctions imposed by the United States and Canada are in contravention of WTO rules," the official said.




"The European Union wants the United States and Canada to abolish the sanctions."




The WTO is to make its decision public on Monday.




The Geneva-based trade body ruled in 1999 that Washington and Ottawa could slap higher tariffs on a list of EU products after it condemned the European Union for banning the use of certain growth-promoting hormones -- used by the US and Canada -- without a scientific assessment of the risk.




The EU had contested these sanctions, saying that they were no longer justified because it had found a scientific basis for banning hormone-treated beef and had updated its law in 2003.




The penalties, in the form of customs tariffs, amount to 116.8 million dollars (74 million euros) for the United States and 11.3 million dollars for Canada.




They target a host of products including French Dijon mustard and Roquefort cheese.




The EU says its ban is based on a study that found consumption of a particular type of hormone was harmful to human health.




The evidence on five other hormones, such as testosterone, was insufficient, but warranted a provisional ban on marketing meat containing those substances because of the uncertainty, according to the EU.




The US and Canada had rejected or raised doubts about the validity of the proof presented by Brussels to back up its ban.

Italy to recall contaminated mozzarella, EU executive 'satisfied'


ROME (AFP) -
The Italian government on Friday decided to begin recalling dioxin-tainted mozzarella from the market as France impounded shipments of the cheese made from buffalo milk in the region around Naples.





The Commission said it was "satisfied" with the move. "There is no reason at this stage to take further action at the EU level," spokeswoman Nina Papadoulaki told journalists in Brussels.




Italian Foreign Minister Massimo D%26#39;Alema earlier Friday said Rome would "this morning ... take the steps agreed with the European Union to withdraw from the market products that do not comply with standards and renew assurances to Italian and foreign consumers," the ANSA news agency reported.




The French government on Friday impounded shipments of mozzarella from Campania, the centre of chronic breakdowns in the waste disposal system that environmentalists say may be behind higher-than-normal levels of dioxin.




Japan and South Korea suspended imports of the cheese after Italian authorities said last week that high levels of dioxin, which increases the risk of cancer, were found in 66 buffalo herds around Naples.




But Rome has said that no tainted mozzarella has been exported, and Agriculture Minister Paolo De Castro insisted at a news conference on Thursday that "there is no health problem."




"It%26#39;s only a matter of a few limited cases in 83 farms out of 1,900 which were immediately isolated," he said.




He also rejected any link between the mozzarella contamination and the waste disposal crisis that engulfed the Naples region at the end of last year.







Overloaded treatment centres have reached the tipping point several times since 1994.





The problem is exacerbated by the local Camorra mafia, which controls many dumps in the region and makes a lucrative business out of shipping in industrial waste from companies in the north.




An animal disease prevention institute in Protici, near Naples, that has been monitoring milk and dairy products from 165 companies since January 2007 has cited dioxin "anomalies" at 25 of them.




The European Commission called late Thursday for urgent action and warned of unspecified steps against Campania, Italy%26#39;s poorest region.




"The commission believes that the measures put in place are not sufficient to ensure that no contaminated product enters the market," a statement said.







This was, it said, because "no recall of product potentially contaminated has been carried out and the surveillance programme on the farms of the Campania region is still too limited."





The commission said it could propose "safeguard measures for dairy products orginating from the region of Campania" if it deems new measures to be insufficient.




Italy produces 33,000 tonnes of mozzarella per year, some 80 percent of it in Campania, where a quarter of a million buffalo are farmed to produce milk for the product.




Buffalo milk mozzarella is a soft cheese served with tomatoes and basil in a Neapolitan speciality, the Caprese salad.

France scraps move to halt mozzarella sales


PARIS (AFP) -
France%26#39;s agriculture minister on Friday scrapped a decision to halt sales of imported mozzarella after Italy decided to recall the dioxin-tainted cheese.





Agriculture Minister Michel Barnier had ordered shops to stop selling mozzarella from Italy%26#39;s Campania region on Friday but later that same day withdrew the measures.




"The European Commission has just said that it was satisfied with the progress shown by the Italian government and sees no need for further European measures at this stage," said the agriculture ministry in a statement.




"The measures previously requested pending additional information from Italian authorities are no longer warranted," he added.




Italian authorities said last week that high levels of dioxin, which increases the risk of cancer, were found in 66 buffalo herds around the city of Naples.




A total of 83 buffalo farms in the Naples region were quarantined.




On Friday, Italy announced a recall of the cheese, a move welcomed by Brussels.




In 2007, France imported 257 tonnes of buffalo mozzarella, according to figures from the dairy industry.

After 40 years, Ebola still highly contagious to the public mind


LIBREVILLE (AFP) -
Popular culture and fears of bioterrorism have stoked the public%26#39;s fear of the Ebola virus, which -- despite terrifying symptoms and high mortality rate -- has only taken 600 lives in 40 years.





"Other diseases like cholera or malaria, kill a lot more people in a day than Ebola has already killed" since its discovery in 1970, said Thomas Geisbert, an American army researcher who was in Libreville for an international congress on the Ebola and Marburg viruses.




Ebola fever was named after a small river in what is now the Democratic Republic of Congo, where it was discovered in 1976. While extremely virulent, experts say the disease is containable because it kills its victims faster than it can spread to new ones.




Nonetheless, according to Geisbert, Ebola rose to notoriety through rumours, Hollywood films and popular fiction. The public%26#39;s fear was only made worse by the virus%26#39; 90 percent mortality rate, he said.




"There are not many micro organisms on the planet that cause 90 percent mortality. That automatically gets interest."




But so does the literature and cinema surrounding it.




"A lot of it started when Ken Alibek, who ran the Soviet Union bioweapon program ... testified in front of the US Congress in the mid-1990s that the Russians were developing Ebola and Marburg bioweapons and when the Soviet Union dissolved nobody knew where the stuff went," said Geisberg.







But he mainly attributes the public%26#39;s awareness of this virus to Richard Preston%26#39;s novel "Hot Zone," in which the virus is discovered in Virginia.





Jean-Paul Gonzalez, research director at the Orstom development research institute and another expert on the virus, cites the film "Outbreak" as further spreading fears of the disease in the public mind.




The blockbuster feature stars including Dustin Hoffman, Morgan Freeman, Rene Russo, Kevin Spacey and Donald Sutherland.




"When the film came out, there was an epidemic in Kikwit (DR Congo) in 1995. The public watched this movie and then news on TV, and they saw that it was somewhat true," he said.




"When we see a woman lying on a bed and vomiting blood and a baby crying nearby, it%26#39;s an image. It sells."




After the September 11, 2001 terrorist attacks, the threat of bioterrorism added another layer to Ebola fears.







"Look at what five anthrax letters did in the United States," said Geisberg, referring to scares in the wake of September 11. "Look at the billions of dollars of impact."





Ebola could be spread quickly, according to Geisberg. If somebody had access to it, they would merely have to "put it in a bottle and kill 40 people in New York City," he said.




But if the illness has been much hyped in western society, in Africa it is a lack of information that has created problems.




"People are told they have to burn clothes, no longer bury their dead the traditional way," said Dr Jean-Jacques Mayembe, from a biomedical research institute in Kinshasa.




"We have succeeded in making people believe that Ebola is the work of witches, namely because of the spectacular effect and the vomiting of blood," said Pierre Fomenty, from the World Health Organisation.




One solution, said Mayembe, is to better inform people about the virus.

20 farms test positive for dioxin in Italian mozzarella scare: minister


ROME (AFP) -
Twenty Italian buffalo farms have tested positive for raised dioxin levels, the country%26#39;s health minister said Friday, as the country began recalling tainted mozzarella from the market.





Nevertheless, Singapore announced it was joining Japan and South Korea in banning Italian mozzarella sales as a precautionary measure.




The southeast Asian city state%26#39;s Agri-Food and Veterinary Authority said the ban was a precautionary measure until laboratory tests could "determine if they have been contaminated with dioxin".




Rome%26#39;s decision to withdraw the famous cheese from sale led the European Union to conclude that no action to protect consumers was necessary, and France quickly reversed a decision to pull imports of the cheese from the shelves.







The scare began last week when samples of mozzarella from the Naples region, which is made from buffalo milk, were found to have raised dioxin levels.





A total of 83 buffalo farms were quarantined. Of those 20 were found to have higher than approved dioxin levels, Under-Secretary of State for Health Gian Paolo Patta told the ANSA newsagency.




A dozen other farms have had quarantine restrictions lifted after testing negative, he added, without giving details for the remainder.




Italy%26#39;s Foreign Minister Massimo D%26#39;Alema said Rome would "take the steps agreed with the European Union to withdraw products that do not comply with standards and renew assurances to Italian and foreign consumers".




The EU commission said it was "satisfied" with the move. "There is no reason at this stage to take further action at the EU level," spokeswoman Nina Papadoulaki told journalists in Brussels.







Initially on Friday, the French government announced it would impound shipments of mozzarella from Campania, but rapidly reversed that decision after Rome%26#39;s announcement that it was withdrawing the cheese from sale.





Dioxin lead to an increased risk of cancer, and environmentalists link the cases to the long-running saga of rubbish disposal in and around Naples, which saw thousands of tonnes of garbage left undealt with at the end of last year.




The Italian government has said that no tainted mozzarella has been exported, and Agriculture Minister Paolo De Castro insisted at a news conference on Thursday that "there is no health problem".




He also rejected any link between the mozzarella contamination and the waste disposal crisis.







The refuse problem has gripped the region since 1994, where a lack of incinerators has led to overflowing landfill tips, which the local mafia is alleged to use for the illegal dumping of toxic waste.





Patta said farms that tested positive would remain quarantined for between 90 and 120 days, to allow the buffalo herds to eliminate the toxin.




"The inquiry will all-encompassing and noone will be excluded," Patta added.




Italy produces 33,000 tonnes of mozzarella per year, some 80 percent of it in Campania, where a quarter of a million buffalo are farmed to produce milk for the product.




Buffalo milk mozzarella is a soft cheese served with tomatoes and basil in a Neapolitan speciality, the Caprese salad.

Radon: The Silent Home Invader That Can Kill


FRIDAY, March 28 (HealthDay News) -- You can%26#39;t see, smell or
taste radon.



The gas emanates naturally from the soil, seeping up into homes that
rest on the ground. The only way to avoid it, really, is to have a house
on stilts.



But the radioactive gas is the leading cause of lung cancer among
nonsmokers in America, as well as the second leading cause of lung cancer
overall, according to the U.S. Environmental Protection Agency. It claims
about 21,000 lives annually.



"It is a health risk you can%26#39;t see," said Kristy Miller, spokeswoman
for the EPA%26#39;s Office of Radiation and Indoor Air. "You can%26#39;t touch it, you
can%26#39;t feel it. It is an inert gas. It%26#39;s in your home for a long time,
leaving no trail of evidence. It%26#39;s only your proactive interest and
testing that%26#39;s going to prevent this health risk."



Radon is a global problem -- the World Health Organization says radon
causes up to 15 percent of lung cancers worldwide.



About one of every 15 homes in the United States is estimated to have a
dangerous radon level, which the EPA defines as more than 4 picocuries per
liter of air.



Radon is produced from the natural decay of uranium, an element found
in nearly all soils. "The earth is always emitting radon at some level,"
Miller said. "It%26#39;s always a part of the outdoor ambient air, in trace
amounts."



The gas typically moves up through the ground to the air above and into
your home through cracks and other holes in the foundation. The home then
traps radon inside.



"A home over the soil can act as a holding tank, allowing radon to
accumulate to high levels," Miller said.



When inhaled, radon can damage the lungs by continuing to emit tiny
bursts of alpha radiation, she said.



"The alpha emitters can actually damage the DNA of the lung tissue,"
Miller said. "The lung is extremely sensitive, compared with the
skin."



Any amount of radon exposure is bad, the EPA says, but the cancer risk
increases over time, as exposure is prolonged.



Because a house%26#39;s radon level depends on many variables -- the
composition of the soil, the construction of the house -- experts warn
that any house might have high levels of the gas.



"Even if you have a new home, you might have high radon," said Bruce
Snead, an extension specialist at Kansas State University specializing in
radiation and indoor air quality. "The only way to know is to test."



The EPA recommends that any homeowner should conduct a radon test. The
tests are easy to obtain. They%26#39;re sold at hardware stores, and some local
health departments and extension services offer to sell them at cost to
homeowners, Snead said.



"People can test a home on their own," he said. "All they have to do is
purchase a test kit, and read and follow the instructions."



The U.S. Surgeon General has recommended that people test their homes
for radon every two years, and retest any time they move, make structural
changes to the home or occupy a previously unused level of a house.



Homeowners also can hire a radon expert to come in and test levels, an
action that some states require as part of a home sale, Snead said. About
20 states have laws requiring notification of radon levels in real estate
transactions, and more are considering it, he said.




"Just as lead is a required notification, should the same thing happen
with radon?" Snead said.




If high levels of radon are discovered, a relatively low-cost home
repair can alleviate the problem, Snead said. The EPA recommends hiring a
qualified radon mitigation contractor to do the work, because lowering
high radon levels requires specific technical knowledge and special
skills.




The most common method of radon reduction is called soil suction. It
prevents radon from entering your home by drawing the radon from below the
house and venting it through a pipe, or pipes, to the air above the house
where it is quickly diluted, Snead said.




"The pipe discharges above the roof line, so this well-known carcinogen
will dissipate into the atmosphere," he said. The pipes can work either
passively, or with a fan used to pull air from the soil.




The average cost of a radon reduction system is about $1,200, according
to the EPA. The cost generally ranges from $800 to $2,500, depending on
the characteristics of the house and choice of radon-reduction
methods.




Some homes now are being built to be radon-resistant, with
gas-resistant foundations and sub-slab fill materials that allow gases to
move easily away, Snead said.




Snead recommends that everyone, homeowner or renter, be proactive in
dealing with the radon that could be building up in their homes.




"We save lives by having tests done and performing mitigation, and by
building houses that are radon-resistant," he said.




More information




To learn more, visit the U.S.
Environmental Protection Agency.

Squid beaks may have medical application


WASHINGTON - The razor-sharp beaks that giant squids use to attack whales %26#151; and maybe even Captain Nemo's submarine %26#151; might one day lead to improved artificial limbs for people.


That deadly beak may be a surprise to many people, and has long posed a puzzle for scientists. They wonder how a creature without any bones can operate it without hurting itself.


Now, researchers at the University of California, Santa Barbara, report in Friday's edition of the journal Science that they have an explanation


The beak, made of hard chitin and other materials, changes density gradually from the hard tip to a softer, more flexible base where it attaches to the muscle around the squid's mouth, the researchers found.


That means the tough beak can chomp away at fish for dinner, but the hard material doesn't press or rub directly against the squid's softer tissues.


Herbert Waite, a professor in the university's department of molecular, cellular %26 developmental biology and co-author of the paper, said such graduated materials could have broad applications in biomedical materials.


"Lots of useful information could some out of this for implant materials, for example. Interfaces between soft and hard materials occur everywhere," he said in a telephone interview.


Frank Zok, professor and associate chair of the department of materials, said he had always been skeptical of whether there is any real advantage to materials that change their properties gradually from one part to another, "but the squid beak turned me into a believer."


"If we could reproduce the property gradients that we find in squid beak, it would open new possibilities for joining materials," Zok said in a statement. "For example, if you graded an adhesive to make its properties match one material on one side and the other material on the other side, you could potentially form a much more robust bond."


The researchers are learning lessons that can be applied to medical materials in the future, said Phillip B. Messersmith of the department of biomedical engineering at Northwestern University.


Messersmith, who was not part of the research team, noted that hard medical implants made of metal or ceramic are often imbedded in soft tissues.


"The lessons here from nature might be useful in transitions between devices and the tissues they are imbedded in," he said in a telephone interview.


Ali Miserez, a UCSB researcher and co-author of the paper, suggested the research could point the way to new types of medical materials.


"We could maybe imagine creating a full prosthesis that mimics the chemistry of the beak, so that it matches the elasticity of cartilage on one side and, on the other side, you could create a material which is very stiff and abrasion resistant," he said in an interview provided by Science.


Waite described the squid beak as like placing an X-Acto blade in a block of fairly firm Jell-O and then trying to use it to chop celery.


The base of the blade would damage the gelatin, but because of the change in density the base of the beak doesn't damage the squid, he pointed out. The squid solves the problem by changing the beak composition progressively, rather than abruptly, so that its tip can pierce prey without harming the squid in the process.


The researchers calculated the changes by carefully measuring the ratios of chitin %26#151; the material in insect shells %26#151; water and proteins in the beaks of Humboldt squid, showing gradual changes from tip to base.


Waite said it was the first time this had been measured. He said he was surprised that the main difference in density resulted from the amount of water included in each part of the beak.


Most people probably know squid best as fried calamari %26#151; the tasty starters popular in many restaurants. But the researchers noted that these are animals that deserve respect.


"Squids can be aggressive, whimsical, suddenly mean, and they are always hungry," Waite said. "You wouldn't want to be diving next to one. A dozen of them could eat you, or really hurt you a lot."


And they are very fast, swimming by a sort of jet propulsion.


The research was funded by the National Institutes of Health, National Science Foundation, NASA and the Swiss National Science Foundation.


___


On the Net:


Science: http://www.sciencemag.org

NYC postpones calorie-posting rule


NEW YORK - Health officials have pushed back a deadline for national chain restaurants to put calorie counts on their menus in New York City outlets.


The requirement was supposed to take effect Monday, but a restaurant trade group has challenged it in court. The city Health Department said Thursday it was postponing the regulation's start date until April 15 because the court ruling is expected soon.


Health officials say the measure will combat obesity by forcing diners to face the caloric consequences of their orders. But the New York State Restaurant Association says the rule violates the First Amendment by forcing businesses to put what amounts to a message on their menus.


Still, one major chain %26#151; Starbucks %26#151; says it will meet the original Monday deadline.

FDA investigates Merck drug-suicide link


WASHINGTON - The Food and Drug Administration said Thursday it is investigating a possible link between Merck's best-selling Singulair and suicide.


FDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.


Merck has updated the drug's labeling four times in the past year to include information on a range of reported side effects: tremors, anxiousness, depression and suicidal behavior.


FDA said it asked the Whitehouse, N.J.-based company to dig deeper into its data on Singulair for evidence of possible links to suicide. The agency said it has not established a "causal relationship" between Merck's drug and suicidal behavior. An agency spokeswoman said the review was prompted by three to four suicide reports it received since last October.


It could take up to nine months before agency scientists can draw any conclusions, FDA said in a posting to its Web site.


The agency recently began notifying the public earlier about possible safety issues. The policy change came after the FDA was criticized for acting too slowly on information about the risks of Merck's painkiller Vioxx and, GlaxoSmithKline plc's diabetes pill Avandia.


Merck officials stressed that the FDA's inquiry is based on reports, not clinical studies %26#151; which are the standard tool for evaluating drug safety. The company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.


"We have no indication that anything about the mechanism of Singulair is consistent with these events," said George Philip, director of research and product development. "But because suicide is a life-threatening event we thought it was important to provide this information in the product label."


Merck said it recently added reports of suicide to Singulair's label, which already listed suicidal thinking and behavior as reported side effects.


In clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.


With sales of $4.3 billion last year, Singulair is used by millions of patients in the U.S, according to Merck. First approved in 1998, it's part of a class of asthma and allergy drugs that includes AstraZeneca's Accolate and Critical Therapeutics's Zyflo.


FDA said it is also reviewing reports of side effects with those drugs. Their labeling does not contain language about suicide.


"Patients should not stop taking Singulair before talking to their doctor," FDA said in its statement, adding that doctors should monitor patients for suicidal behavior and mood changes.


Shares of Merck %26 Co. Inc. rose 8 cents to close at $44.78.

FDA investigates Merck drug-suicide link


WASHINGTON - The Food and Drug Administration said Thursday it is investigating a possible link between Merck's best-selling Singulair and suicide.


FDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.


Merck has updated the drug's labeling four times in the past year to include information on a range of reported side effects: tremors, anxiousness, depression and suicidal behavior.


FDA said it asked the Whitehouse, N.J.-based company to dig deeper into its data on Singulair for evidence of possible links to suicide. The agency said it has not established a "causal relationship" between Merck's drug and suicidal behavior. An agency spokeswoman said the review was prompted by three to four suicide reports it received since last October.


It could take up to nine months before agency scientists can draw any conclusions, FDA said in a posting to its Web site.


The agency recently began notifying the public earlier about possible safety issues. The policy change came after the FDA was criticized for acting too slowly on information about the risks of Merck's painkiller Vioxx and, GlaxoSmithKline plc's diabetes pill Avandia.


Merck officials stressed that the FDA's inquiry is based on reports, not clinical studies %26#151; which are the standard tool for evaluating drug safety. The company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.


"We have no indication that anything about the mechanism of Singulair is consistent with these events," said George Philip, director of research and product development. "But because suicide is a life-threatening event we thought it was important to provide this information in the product label."


Merck said it recently added reports of suicide to Singulair's label, which already listed suicidal thinking and behavior as reported side effects.


In clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.


With sales of $4.3 billion last year, Singulair is used by millions of patients in the U.S, according to Merck. First approved in 1998, it's part of a class of asthma and allergy drugs that includes AstraZeneca's Accolate and Critical Therapeutics's Zyflo.


FDA said it is also reviewing reports of side effects with those drugs. Their labeling does not contain language about suicide.


"Patients should not stop taking Singulair before talking to their doctor," FDA said in its statement, adding that doctors should monitor patients for suicidal behavior and mood changes.


Shares of Merck %26 Co. Inc. rose 8 cents to close at $44.78.

Patients rate local hospitals


WASHINGTON - What do former patients think about the care they received at your local hospitals? The government wants to make it easier for you to find out.


Federal health officials in recent years have made strides to improve transparency in health care. But measuring how well hospitals do their job can be technical. New patient satisfaction scores, which went online Friday, cover basic premises that just about every hospital patient and their family members can understand.


For example:


_Did doctors treat patients with courtesy and respect?


_How often were the room and bathroom cleaned?


_Was the area around the room quiet?


_Did the patient get immediate help after pressing a call button?


Those questions were included in a survey used to evaluate more than 2,500 hospitals around the country.


"You don't have to be a technical expert to understand this information and its implications," said Joyce Dubow, senior adviser at the AARP, the senior advocacy group. "If you ask somebody whether they were cared for with respect, they get that."


Health and Human Services Secretary Mike Leavitt said consumers %26#151; and the Medicare program %26#151; pay for care whether it's good or not. Informing consumers about how well a hospital performs a particular task or how much it charges for a particular service will serve as incentives for health care providers to do better.


"The current sector is all about volume," Leavitt said. "The future is about value."


The government's Web site, http://www.hospitalcompare.hhs.gov, lets consumers compare up to three hospitals. Users will be able to see the scores for such things as how often nurses communicated well with their patients; hospitals nationwide averaged 73 percent on that particular question. Consumers will also be able to see how well the average hospital in their state fared on each question.


The data was collected by hospitals from a random sample of patients from October 2006 and June 2007. The government led development of the survey, which was administered 48 hours to six weeks after the patients were discharged.


Federal officials said they recognize that patients needing emergency care won't use the comparison Web site, nor should they. However, more than 60 percent of all patients go to a hospital for elective procedures.


The site will also help hospitals focus improvements where patients feel it is most needed, said Rich Umbdenstock, president and CEO of the American Hospital Association.


"Ultimately, this tool benefits everyone," Umbdenstock said.


Overall, federal officials said rural hospitals seemed to fare better than urban ones when it came several measures of patient satisfaction.


"I think that has to do with rural hospitals being more of a fabric of the community," said Herb Kuhn, acting deputy administrator at the Centers for Medicare and Medicaid Services.


Officials acknowledge that few consumers compare quality information about insurance plans, hospitals and other providers to make decisions about their care. A recent Kaiser Family Foundation survey estimated that fewer than one in five patients did. However, that's an increase from 12 percent in 2000.


Leavitt acknowledged that the government's efforts to evaluate the quality of health care are lacking. He likened the current situation to the earliest of video games, a table tennis game called Pong.


"We're not very good at this, but we're making a lot of progress," he said.


__


On the Net:


Hospital Compare: http://www.hospitalcompare.hhs.gov

Bat and vaccine breakthrough in fight against Ebola, Marburg


LIBREVILLE (AFP) -
Experts say they are making progress in the battle against the horrifying Ebola virus with a congress here told that a vaccine could be ready in five years.





Scientists also told the first world congress on the Ebola and related Marburg virus to be held in Africa that the fruit bat is probably the main carrier of the viruses though it never falls victim to the disease.




Ebola and Marburg, which both cause agonising haemorrhagic fevers and severe internal bleeding, are estimated to have killed between 600 and 2,500 people since they first emerged in the mid-1970s.




Experts at the weeklong conference which ended Friday said that Ebola could become more widespread unless more resources are put into the fight to eradicate it.




Boston University researcher Thomas Geisbert said vaccines against Ebola and Marburg could be developed within "four, five or six years". He said shots that work on monkeys have been developed.




Much attention has also been put on the role of the fruit bat in spreading the highly contagious virus.




Xavier Pourrut of the Franceville International Centre for Medical Research described the fruit bat as a "natural reservoir" for Ebola and Marburg.




The fruit bat carries the virus without being infected and can spread it to other animals or humans, a discovery which should help protect populations, experts said.




Pierre Formenty, a World Health Organisation expert, said: "In the long term we%26#39;ll work on understanding the immune systems that allow them (bats) to survive the infection" adding this could pave the path for more effective vaccines and treatments.




Formenty said "we cannot eradicate Ebola and Marburg, but there are solutions so that we can live with it."




Ebola can be contained if people are well informed and hospitals take preventive measures.




But the experts said more research money needs to be spent on Ebola and Marburg.




"Malaria, tuberculosis and AIDS kill more people. Malaria kills 1,000 children every day," Formenty said, warning that if Ebola and Marburg are ignored, there could be more outbreaks and the viruses could become stronger.




"In the 1960s AIDS was only an emerging virus." he said.

Praying parents' other 3 kids removed


WAUSAU, Wis. - The three siblings of a girl who died of diabetes that went untreated as her parents prayed instead of taking her to a doctor have been removed from the home during an investigation, police said Friday.


The parents and social services experts agreed the move would be best for everyone, Everest Metro Police Chief Dan Vergin said. The children are staying with other relatives, though they were not in danger, he said.


"There is no physical evidence of abuse or neglect," he said.


Madeline Neumann, 11, died Sunday the Weston home of an undiagnosed but treatable form of diabetes as her parents, Dale and Leilani Neumann, prayed for her to get better. Her mother said she never expected her daughter, whom she called Kara, to die.


The family believes in the Bible, which says healing comes from God, Leilani Neumann said.


The children removed from the home range in age from 13 to 16 and are expected to return to their parents once an investigation of the girl's death wraps up, Vergin said.


He would not specify where they are living, other than with another family member.


Vergin said his agency's final report will make no recommendations on possible charges against the parents, leaving that up to the district attorney.


"There is no intent. They didn't want their child to die. They thought what they were doing was the right thing," he said. "They believed up to the time she stopped breathing she was going to get better. They just thought it was a spiritual attack. They believed if they prayed enough she would get through it."

Vytorin heart study expanded, results being delayed


CHICAGO (Reuters) -
U.S. researchers said on Friday they
plan to expand the size of a major study to determine the heart
benefits of the controversial cholesterol fighter Vytorin,
which they said would delay results until 2012.


Vytorin combines the statin Zocor, known generically as
simvastatin with another cholesterol medicine, Zetia or
ezetimibe, and is marketed by a joint venture of Merck %26 Co and
Schering-Plough Corp.


The study tests Vytorin against Zocor alone, which is now
available in cheaper, generic form. The companies hope to show
added benefits from the combination drug.


Academic researchers running the trial said in a statement
they would expand the study to 18,000 patients to strengthen
the results, which aim to show that the drug prevents heart
attacks and other heart problems. The study, originally
designed for 10,000 patients, is expected to be completed in
2011.


Trial chairman Dr. Eugene Braunwald of Brigham and Women%26#39;s
Hospital said in a statement that expanding the trial will
allow researchers to test definitively whether the additional
lowering of low-density lipoprotein -- or LDL, the so-called
bad cholesterol -- with Zetia will translate into additional
benefits for patients.


Researchers have been awaiting the results of the study,
dubbed "IMPROVE-IT," to resolve questions raised by an earlier
study released in January that suggested the higher-priced
combination drug Vytorin fared no better than an inexpensive
statin in patients with an inherited form of heart disease.


In January, Merck and Schering-Plough announced that
Vytorin did not stop the accumulation of fatty deposits in
arteries any better than Zocor in these high-risk patients.


While Vytorin significantly reduced cholesterol levels, it
did not slow the disease any better than Zocor alone.


That trial, known as ENHANCE, has garnered intense investor
interest because Vytorin and Zetia have annual sales of about
%26#36;5 billion, and are important to future earnings growth of the
companies.


And because it took the companies nearly two years to
release the ENHANCE results, Michigan Democratic Reps. John
Dingell, chairman of the Committee on Energy and Commerce, and
Bart Stupak, chairman of the Subcommittee on Oversight and
Investigations, said they suspect the drugmakers suppressed the
data to protect their profits.


They said they are investigating the way Merck and
Schering-Plough handled the study and have asked the U.S. Food
and Drug Administration for records related to television
commercials promoting the drug.


Many experts have said the question of whether adding the
drug Zetia to further lower LDL cholesterol actually helps
patients avoid heart problems will not be fully settled until
the IMPROVE-IT results are released.


"It%26#39;s that much longer before you get any answers," said
Dr. Harlan Krumholz of Yale University, responding to news of
the delay.


Krumholz will serve on a panel of experts that is set to
discuss the full ENHANCE study results on Sunday at a meeting
of the American College of Cardiology in Chicago.


(Additional reporting by Bill Berkrot; Editing by Gary
Hill, Richard Chang)

Colo. town closer to drinkable tap water


DENVER - High concentrations of chlorine being used to purge salmonella from a southern Colorado town's water system were expected to drop far enough Saturday that residents could use the water for showering.


The disinfection process in Alamosa began Tuesday, five days after officials confirmed the presence of the bacteria in the water. The source is still unknown.


Nearly 300 people have become ill, with 73 cases of salmonella confirmed.


During the cleansing, the chlorine level in Alamosa's tap water is more than five times greater than what's needed to keep a swimming pool clean. Authorities say it could be April 7 before levels are low enough in the 50-mile network of pipes that residents can drink the water.


In the meantime, volunteers and the National Guard are passing out clean water at distribution points, and officials say the tap water is usable only for flushing toilets.


Salmonella can cause diarrhea, fever and stomach pain. Victims typically recover on their own, but the elderly, infants and people with impaired immune systems may require treatment.


Salmonella bacteria are usually food-borne, and contamination of public water systems is rare.


Officials have identified the strain of salmonella in the water system as one commonly found in the feces of birds, deer and other warm-blooded animals around the agricultural community of 8,500.


Alamosa's water is drawn from a deep well and had been the largest of about 100 water systems in the state that didn't require chlorination. City plans called for a new water plant, already being built, to include chlorination even before the salmonella outbreak.

Sound monitors protect premature babies


INDIANAPOLIS - Warning lights hover over the snoozing patients in Riley Hospital for Children's neonatal intensive care unit, ready to flash whenever sound levels creep beyond normal conversation. As decibels rise, the colors on the new monitoring system change from green to yellow to red, hushing chatty parents or doctors so the babies get the rest they need to develop.


Noise louder than roughly the level of conversation can cause premature or sick babies' hearts to beat too fast or too slowly, said Dr. William Engle, a neonatologist at Riley. And interfering with babies' vital signs or sleep can slow development and healing because their bodies do most of that work while they sleep.


"The function of babies is to grow and develop, and in between they eat," he said.


Preemies also need quiet so they can learn their mother's voice and their brains can figure out how to process sound, things that normally happen in the last trimester before birth.


"It's definitely a great idea," Dr. Bob White, a neonatologist at South Bend's Memorial Hospital, said of the monitoring system in Riley's neonatal intensive care unit, or NICU.


White, who is not involved in creating or distributing the system, helped write national noise standards for NICUs that have been adopted by the American Institute of Architects and are used in most hospital design.


Inventor Chris Smith hopes doctors around the country agree with White. He has sold his Sonicu system to several Indiana hospitals and wants to expand nationally.


Smith, 43, had no training as a sound engineer and no plans to become an entrepreneur when his son Sean was born five weeks premature in 2000. But he noticed Sean flinch in response to bright light in the NICU of St. Vincent Indianapolis Hospital, and he wound up designing a system to soften the unit's lighting.


Then the nurses asked him what he could do about sound.


"That's really when I realized that there was no good way out there to measure sound, other than your standard, hand-held meter," he said.


Babies born too soon lose the muffling effect of the womb before their ears can filter sound, White said.


"The sounds ... come from all different directions and all different sources, and they're often associated with unpleasant sensations for the baby," White said.


NICUs are rife with noise pollution created by employees, equipment and excited family members.


"There's no good way for the nurses or doctors to walk up to a parent, tap them on the shoulder and say, 'You're being too loud,'" Smith said. "That's confrontational."


The former car mechanic filled hours of spare time in the evenings and on weekends researching sound standards and building a system.


Smith, who tinkered in radio and TV electronics in high school, hired an acoustical engineer to help. They created a ceiling-mounted system of microphones that picked up sound and funneled data back to a large control panel.


"There was a lot of wiring, a lot of labor, a lot of programming," he said.


St. Vincent paid around $100,000 for the system, which it installed about five years ago. Smith had no interest in shopping his invention to other hospitals because the work took so much time.


Then Riley Hospital, also in Indianapolis, called a few months later.


"They basically said, 'I want that,'" he said.


The latest version of Sonicu can feed a stream of both sound and light data digitally to a computer. It offers the cone-shaped warning lights and can quickly dim the lighting in a room that gets too noisy. It also can make lighting mimic the sun by brightening toward noon and then fading, which also helps babies sleep well.


White, the neonatologist who helped write the national standards, said he knows of no other NICU monitoring system that sophisticated.


Smith has sold systems to a handful of Indiana hospitals, so far to good reviews. He said the systems can cost anywhere from $40,000 to $400,000, depending on each hospital's needs.


The monitors have taught hospital staff to limit the number of groups making rounds at the same time because having more than one group in a room raises noise levels dramatically.


Most NICUs are filled with noise that can't be helped, White said. Fans in the heating and ventilation system have to operate almost constantly, and the monitors need to beep.


The Sonicu system reins in the main noise maker that can be controlled.


"People think, 'Oh gosh, I didn't realize, I'll go over here so I won't have to talk so loud,'" White said. "It really is something that addresses the human factors that we do have some control over."

Poor Sense of Smell May Be Early Sign of Parkinson's


FRIDAY, March 28 (HealthDay News) -- An impaired sense of smell
could be an early indicator of Parkinson%26#39;s disease, occurring up to four
years before motor skill problems appear, recent research shows.



The study, published in the February issue of the Annals of
Neurology
, followed 2,267 men who received olfactory testing at the
Kuakini Medical Center in Honolulu at least once during two periods in the
1990s. They were followed for up to eight years and, during that time, 35
of the men developed the disease.



An odor identification problem preceded the development of Parkinson%26#39;s
by at least four years in these men. Decreased odor identification was
associated with older age, smoking, more coffee consumption, less frequent
bowel movements, lower cognitive function and excessive daytime
sleepiness, but even after adjusting for these factors, those with the
lowest odor identification scores had a five times greater risk of
developing Parkinson%26#39;s than those with the highest scores.



The results strengthen findings from earlier studies that suggest
olfactory impairment begins between two and seven years before
diagnosis.



Why problems with smelling accompany Parkinson%26#39;s is not completely
understood; however, nerve loss and the formation of Lewy bodies --
abnormal clumps of proteins inside nerve cells that are thought to be a
marker of the disease -- are known to take place in the olfactory
structures of patients with the disease.



The study authors noted that one previous study involving brain
dissection of deceased patients with neurological disease found that
olfactory structures are the earliest brain regions affected by Lewy
degeneration, which supports the idea that an impaired sense of smell
could be one of the earliest signs of Parkinson%26#39;s disease.



An impaired sense of smell could also be caused by impaired sniffing,
which may be another motor symptom of Parkinson%26#39;s.



Olfactory testing, along with screening for other potential early
indicators of Parkinson%26#39;s disease such as constipation or sleep
disturbances, could provide a simple and relatively economic means of
identifying individuals at high risk who could participate in trials of
medications designed to prevent or slow disease progression, the authors
concluded in a prepared statement.



More information



The National Institute of Neurological Disorders and Stroke has more
about Parkinson%26#39;s disease.

Key Protein Limits Damage of Heart Attack


FRIDAY, March 28 (HealthDay News) -- A signaling protein called
Gi plays a critical role in protecting the heart during a heart attack,
say researchers at Thomas Jefferson University in Philadelphia.



It was already known that Gi increased activity in a failing heart, but
it wasn%26#39;t clear whether the protein was helping the heart adapt to damage
or if it actually caused more heart cells to die.



In this study, the researchers created mice that lacked a working Gi
gene, simulated a heart attack, and then restored blood flow to the heart.
These mice suffered more heart damage than mice with a normally
functioning Gi gene.



"It appears that in this setting, Gi is an important protective
mechanism," team leader Walter Koch, a professor of medicine and director
of the Center for Translational Medicine at Jefferson Medical College,
said in a prepared statement.



"The heart wants to activate Gi and attempt to protect cardiac myocytes
from dying. We found that in this acute setting, heart attacks are bigger
when Gi is blocked," he said.



The study was published in the March 18 issue of
Circulation.



Gi plays an important role in intracellular signaling, similar to a
molecular switch, explained Koch. Gi is not a new drug target, but the
activation of certain receptors (such as beta-2 adrenergic receptors) that
also turn on Gi could be drug targets.



Koch said developing a "class-specific Gi inhibitor" is a vital step in
learning more about Gi%26#39;s role and behavior.



"We don%26#39;t have to worry about what the receptor we are blocking; we%26#39;re
blocking a receptor that couples with Gi. We never had the tools before to
tell if Gi activation was good or bad. We think that we can now begin to
test the role of Gi in cardiac injury," Koch said.



More information



The American Heart Association has more about heart attack.

Lung Capacity Declines Faster With Diabetes


FRIDAY, March 28 (HealthDay News) -- Diabetes, the leading cause
of heart disease, stroke, blindness, kidney failure and non-traumatic
amputations, can also cause the lungs to deteriorate quicker than they
normally do with age, a new study shows.



Although everyone experiences a decline in lung function as they grow
older, research published in the April issue of Diabetes Care
concluded that the lungs of people with type 2 diabetes deteriorate more
quickly than normal.



The Johns Hopkins team that conducted the research, part of a larger
investigation known as the Atherosclerosis Risk in Communities (ARIC)
study, found in previous research that reduced lung function predicted and
preceded the development of type 2 diabetes.



In this latest study, there was an average difference of 6 millimeters
more decline per year in forced vital capacity (FVC), a measure of how
well the lungs fill with air, said study author Hsin-Chieh Jessica
Yeh.



The scientists suggest the accelerated reduction in forced vital
capacity (FVC) found in people with diabetes could be the result of high
blood sugar levels stiffening lung tissue or fatty tissue in the chest and
abdomen restricting the lungs.



The ARIC is a prospective cohort study of 15,792 adults from four U.S.
communities. The present analysis, which looked at 1,100 diabetics and
10,162 non-diabetics, was based on three years of follow-up.



"This study confirms the results of five previous studies, which
demonstrated lower lung function in diabetic subjects compared with their
non-diabetic counterparts," said Dr. Guillermo E. Umpierrez, an associate
professor of medicine at Emory University and section head of Diabetes and
Endocrinology at the Grady Health System, both in Atlanta. "These studies
also demonstrated a higher annual rate of lung function decline in the
diabetic compared with the non-diabetic population. Although the
information is not novel, this report enhances recognition of the lung as
a target of diabetic injury."



Most of the diabetic participants in the current study had type 2
diabetes, so the scientists were not able to look at decreases in lung
function among type 1 diabetics, who have to use insulin on a daily
basis.



"On the other hand, we found diabetes severity, as indicated by
intensity of anti-diabetic treatment, was associated with greater rate of
FVC decline. Patients on insulin treatment, alone or with oral
medications, had the greatest decline in forced vital capacity compared to
their non-diabetic counterparts," Yeh explained.



In an accompanying editorial, Dr. Connie Hsia, of the University of
Texas Southwestern Medical Center, cautioned that using inhaled insulin
might trigger or exacerbate the pulmonary dysfunction found in people with
diabetes.



"However, since none of our study participants were on inhaled insulin,
our study did not have direct implications on the use or absorption of
inhaled insulin," Yeh said.



Umpierrez pointed out that the use of inhaled insulin needs more study.
"The future of inhaled insulin for treatment of diabetes is uncertain;
however, some pharmaceutical companies continue to investigate the safety
and efficacy of inhaled insulin as an alternative of insulin injections,"
he noted.



Diminished lung capacity may lead to lower oxygen delivery to all body
tissues, he noted, although the drop in lung function among diabetics in
this study appears to be small. However, in elderly patients with
long-standing diabetes, impairment of lung capacity could worsen the risks
of adverse outcomes should the elderly diabetic develop pneumonia, heart
failure, volume overload or vascular complications, he added.



"Traditionally, the lung is not treated as a target organ for diabetes
complication. Based on the current study, we suggest physicians add lung
function on the watch list as they care for their diabetes patients," Yeh
said.



More information



For more on diabetes, visit the American Diabetes
Association.

Hormone Combo May Provide Reversible Male Birth Control Tool


FRIDAY, March 28 (HealthDay News) -- A combination of
testosterone and progestin suppresses sperm production faster and more
completely than testosterone alone, according to an analysis by an
international team of researchers.



The scientists said that hormonal contraception may become a safe,
effective and reversible form of male birth control.



"It is possible to suppress sperm output to concentrations that are
comparable with reliable contraception in most, but not all men. The rate
of suppression is comparable to that achieved after a vasectomy," lead
author Peter Y. Liu, an associate professor at the University of Sydney,
Australia, said in a prepared statement.



Testosterone and other male hormones create "negative feedback" in the
male reproductive system, which suppresses sperm production.



In this study, Liu and colleagues analyzed 30 male hormonal
contraceptive studies that included a total of 1,756 men, aged 18 to 51.
In these studies, conducted from 1990 to 2006, the men received different
preparations of testosterone, with or without various preparations of the
hormone progestin.



Testosterone is the primary male sex hormone. Progestin (a synthetic
progesterone), which is used in combination with estrogen for female
contraception, is not ordinarily produced by men.



The analysis revealed that the combination of testosterone and
progestin was more effective at suppressing sperm production that
testosterone alone.



"Progestin co-administered with testosterone increased both the rate
and extent of suppression. It also may make long-term hormonal
contraception safer by reducing the dose of testosterone needed for
maintenance contraception," Liu said.



The analysis also showed that treatment suppressed sperm output more
quickly in white males but not as completely as in non-whites. Younger men
with lower testosterone levels also had faster sperm production
suppression.



The review authors also found that it%26#39;s difficult to predict which men
will respond best to this combination hormonal contraception.



"Considerable progress has been made toward finding an effective
combination of these two hormones. However, the current analysis didn%26#39;t
take into account the different types of progestins, so more research will
need to be done to find the optimum therapy," Liu said.



The study was published in the Journal of Clinical Endocrinology
%26 Metabolism
.



More information



The American Academy of Family Physicians has more about birth control.

Premature Delivery Linked to High Cholesterol in Moms Later


FRIDAY, March 28 (HealthDay News) -- Giving birth early seems to
increase a woman%26#39;s risk of having high cholesterol later, a new study
shows.



And that raises the chances of heart disease even further down the line
for these women, the researchers added.



The findings were presented Thursday at the Society for Gynecologic
Investigation annual meeting, in San Diego.



"Total cholesterol and LDL cholesterol were elevated in women who%26#39;d had
a preterm birth, before 34 weeks," said study author Janet Catov, an
assistant professor of obstetrics, gynecology and reproductive sciences at
the University of Pittsburgh School of Medicine.



Catov said it%26#39;s hard to know yet whether there%26#39;s something in the
pregnancy or preterm delivery that triggers the high cholesterol, or if
it%26#39;s the high cholesterol that may have something to do with the preterm
delivery. She did note that "very early in pregnancy, women with preterm
birth have elevated lipids, which may be exacerbated in pregnancy."



Another recent study found that women with very low levels of
cholesterol were also at risk of preterm birth, but Catov said this study
showed that women on the very high end of cholesterol levels also went on
to give birth prematurely.



"Perhaps there%26#39;s a normal range, and if you%26#39;re higher or lower, it
could be a problem," she said.



In the current study, Catov and her colleagues compared 47 women who%26#39;d
had a preterm birth, defined as giving birth before 37 weeks of gestation,
to 104 women who gave birth to full-term infants. Most of the women in the
preterm group gave birth before 34 weeks of gestation.



Women who had other chronic medical conditions, such as preeclampsia or
a baby with signs of growth restriction, were excluded from the study.



Blood samples were taken an average of 7.4 years after delivery.



Women who%26#39;d given birth before 34 weeks of gestation had the highest
levels of total cholesterol at 202.6 mg/dl. Women who gave birth between
34 and 37 weeks had levels of 190.1 mg/dl, and women who carried their
babies to term had levels of 180.1 mg/dl.



After adjusting for race, smoking history and body mass index, the
researchers found that women who gave birth prematurely had a 2.3 times
greater risk of developing cholesterol levels above 240 mg/dl, a level
considered high risk by the American Heart Association.



Additionally, women who%26#39;d had a preterm birth were 3.3 times more
likely to have elevated LDL -- the "bad" cholesterol -- than women who
gave birth to full-term babies.



"What this study tells us is that a woman%26#39;s previous medical history,
particularly conditions that happen during pregnancy, may be a clue to her
later heart disease risk," said Dr. Nieca Goldberg, director of the New
York University Medical Center%26#39;s Women%26#39;s Heart Program.



"I would advise a woman who%26#39;s had a preterm birth and who now has high
cholesterol to have her cardiac risk factors evaluated at regular
intervals, at least with a yearly physical," said Goldberg.



While Catov said these findings need to be duplicated in a larger study
before any specific guidelines or recommendations can be made, she said
it%26#39;s a good idea to "keep your doctor apprised of your medical conditions
and preterm births or other adverse pregnancy outcomes, and keep up to
date with recommended screenings."



More information



To learn more about cholesterol and how to lower your levels, visit the
American Heart Association.

Smokers at Increased Risk of Aneurysm Recurrence


FRIDAY, March 28 (HealthDay News) -- Smokers with a brain
aneurysm who are treated with coil embolization are more likely than other
patients to develop another aneurysm, according to a U.S. study.



If a brain aneurysm bursts, the bleeding vessel causes a stroke.



During coil embolization, a catheter is inserted into an artery in the
groin and then threaded to the affected area of the brain. One or more
tiny coils are fed through the catheter and placed in the aneurysm. The
body forms a blood clot around the coil, which blocks the aneurysm.



Neurological surgeons at Jefferson Hospital for Neuroscience in
Philadelphia reviewed patient records from 2003 and found that cigarette
smokers -- especially those with low-grade subarrachnoid hemorrhage -- who
received this treatment were at increased risk for aneurysm recanalization
(re-opening). The amount of cigarettes smoked affected the level of
risk.



The researchers found no correlation between increased risk and
aneurysm location and size, type of coil, or coil compaction.



The study -- believed to be the first to document a link between
aneurysm recurrence and smoking -- was published in the April issue of
the Journal of Neurosurgery.



"Of the various factors that lead to a predisposition for these
cerebral aneurysms, cigarette smoking is the only factor that has
consistently been identified in all the populations studied and is also
the most easily preventable," Dr. Erol Veznedaroglu, an associate
professor of neurological surgery and director of the division of
neurovascular surgery and endovascular neurosurgery at Jefferson Medical
College, said in a prepared statement.



The study authors noted that previous research had established a direct
link between cigarette smoking and increased risk of brain aneurysm
formation and growth, but "despite this evidence, more than one third of
prior smokers continue to use nicotine after suffering an aneurysm,
especially patients who started smoking at a young age and those with a
history of depression or alcohol abuse."



While this study didn%26#39;t find a significant association between smoking
cessation and aneurysm recurrence, Veznedaroglu said "patients with known
cerebral aneurysms should be aggressively counseled about the risk of
cigarette smoking."



More information



The Brain Aneurysm Foundation has more about treatment
options.

New Drugs No Better Than Older Ones for Schizophrenia


FRIDAY, March 28 (HealthDay News) -- Newer, so-called
second-generation antipsychotics are no better than the older drug
haloperidol in treating a first episode of schizophrenia, a new study
finds.



However, it appears that more patients prefer the newer drugs and are
more likely to continue using them than haloperidol, the study authors
said.



"When we compared newer drugs to older drugs, we found that patients
stay longer on the new drugs," said lead researcher Dr. Rene Kahn, a
professor of psychiatry at the University Medical Centre Utrecht in the
Netherlands.



Earlier studies had found 70 percent of schizophrenia patients stopped
taking the older antipsychotics. In the new study, 70 percent of patients
kept with the newer drugs, Khan noted.



"The biggest reason that they stayed longer was that doctors perceived
the newer drugs as more efficacious," Khan said. "That%26#39;s the way real life
is -- real life is that patients and doctors perceive their medication to
have a certain efficacy."



But, if you look at improvement in symptoms and the number of times
patients were hospitalized after the first treatment, then the drugs did
not differ, Khan said.



The findings are published in the March 29 issue of The
Lancet
.



Kahn%26#39;s team randomly assigned 498 patients to haloperidol, or
higher-dose second-generation drugs that included amisulpride, olanzapine,
quetiapine and ziprasidone.



Over the following year, 63 patients discontinued haloperidol, compared
with 32 who stopped using amisulpride, 30 who stopped using olanzapine, 51
who quit quetiapine and 31 who stopped taking ziprasidone, the researchers
found.



However, regardless of which medication the patients were taking, 60
percent saw a reduction in their symptoms, the researchers found. And,
when the researchers looked at gender, and side effects such as suicidal
behavior and substance abuse, they didn%26#39;t find any significant difference
among the drugs.



The hopeful sign is that patients taking the newer drugs stayed on them
longer, Khan said.



"Overall, we should be encouraged that if we give the patients the
right drug, that in 60 to 70 percent of the cases, they still stay on the
medication," Khan said. "We should not be so pessimistic, as earlier
studies suggested, that we cannot treat schizophrenia because only 30
percent of the patients stayed on the drug."



Dr. Robert A Rosenheck, a professor of psychiatry at Yale University
School of Medicine and author of an accompanying editorial in the journal,
said the only way to test whether patients prefer the newer drugs to the
older ones is to have an objective trial in which patients and doctors
don%26#39;t know who%26#39;s getting which drug.



"In terms of the main outcome of how long patients stayed on their
drugs, the study showed a benefit for the newer drugs," he said. But,
since the doctors knew which drugs were being given, the study results
likely reflected the doctors%26#39; opinions of the drugs, he added.



The study began in 2002, Rosenheck noted, when there was a lot of
enthusiasm for these new drugs. "The assumption of many doctors was, %26#39;I
want my patients on newer drugs as soon as possible,%26#39; " he said.



"The only way you get an objective assessment is by doing a study in
which you can be sure neither the patient nor the physician knows which
drug it is. So, they are just judging by the clinical outcomes. That%26#39;s the
standard for evaluating drugs," Rosenheck said.



More information



For more on schizophrenia, visit the U.S. National Institute of Mental Health.

Biomarker May Signal HIV Progression


FRIDAY, March 28 (HealthDay News) -- Researchers at Temple
University think they may have found a blood marker that denotes the
progression of the virus that causes AIDS.



The researchers found an increase in the CD163+/CD16+ monocyte subset
may coincide with the advancement of human immunodeficiency virus (HIV),
according to a study published in the March issue of AIDS Research and
Human Retroviruses
.



"It looks like, based on these correlations, that this particular cell
type may be involved in immune impairment and the progression of HIV," Jay
Rappaport, a professor of neuroscience and neurovirology who oversaw the
study, said in a prepared statement. "Is it a good prognostic indicator?
If you have a lot of these monocytes, does it mean you are going to
progress into AIDS faster? Right now, all we know is what the correlations
are."



A monocyte is a specific white blood cell, a part of the human body%26#39;s
immune system that protects against blood-borne pathogens and moves
quickly to sites of infection within the body%26#39;s tissues. As monocytes
enter tissue, they undergo a series of changes.



The researchers investigated these alterations by examining 18 patients
with HIV and seven individuals without HIV.



"We did, indeed, find that patients with detectable virus had an
increase of this monocyte subset that correlated with the amount of virus
they had in their blood," study author Tracy Fischer-Smith, an associate
scientist in Temple%26#39;s Neuroscience Department, said in a prepared
statement. "We were surprised to find that in patients with CD4+ T-cell
counts of less than 450 cells per microliter [200 or less per microliter
is defined as AIDS], the increase of this monocyte subset correlates
inversely with the number of T-cells."



Fischer-Smith said this finding suggests that as the monocyte cells are
increasing, these patients are losing CD4+ T-cells, which are critical for
maintaining one%26#39;s immune system.



"This may actually provide an earlier window into what is happening
with HIV-infected patients where we might be able to see that immune
impairment is taking place before we see a dramatic loss of CD4+ T-cells,"
she said.



The researchers plan to expand this study by following a cohort of
patients over time to see if their findings can provide doctors with an
early warning system and help them design better therapeutic strategies,
Fischer-Smith said.



More information



The U.S. Department of Health and Human Services has more about HIV and AIDS.